BSO-07

• Description :

  BSO-07 is a ROS/JNK activator with significant anticancer effects, having an IC50 value of 24.81 μM against human breast cancer (BC) cells. BSO-07 induces apoptosis (Apoptosis) and paraptosis by activating JNK and increasing ROS levels, including enhancing the expression of apoptosis-associated proteins such as PARP, Bax, phosphorylated p53, ATF4, and CHOP, while decreasing the levels of anti-apoptotic proteins like Bcl-2, Bcl-xL, and Survivin. BSO-07 holds promise for research in the field of breast cancer[1].

• UNSPSC :

  12352101

• Target :

  JNK; Reactive Oxygen Species (ROS)

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bso-07.html

• Smiles :

  ClC1=CC=C(N2CCN(CC3=NO[C@@](CCC4)([H])[C@@]4([H])[C@H]3C5=CC=CC=C5)CC2)C(F)=C1

• Molecular Formula :

  C24H27ClFN3O

• Molecular Weight :

  427.94

• References & Citations :

  [1]Kim NY, et al. Oxazine drug-seed induces paraptosis and apoptosis through reactive oxygen species/JNK pathway in human breast cancer cells. Transl Oncol. 2024 Nov;49:102101.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported